Compare FCFS & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCFS | KYMR |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.6B |
| IPO Year | 1996 | 2020 |
| Metric | FCFS | KYMR |
|---|---|---|
| Price | $212.90 | $114.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 26 |
| Target Price | ★ $210.67 | $107.72 |
| AVG Volume (30 Days) | 417.2K | ★ 1.2M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $3,661,043,000.00 | $39,211,000.00 |
| Revenue This Year | $16.20 | $10.61 |
| Revenue Next Year | $8.35 | $8.17 |
| P/E Ratio | $88.54 | ★ N/A |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $119.21 | $36.88 |
| 52 Week High | $235.97 | $130.05 |
| Indicator | FCFS | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 62.29 |
| Support Level | $206.05 | $76.40 |
| Resistance Level | $231.35 | $120.90 |
| Average True Range (ATR) | 7.79 | 5.87 |
| MACD | -0.59 | -0.87 |
| Stochastic Oscillator | 38.77 | 62.96 |
FirstCash Holdings Inc is an operator of pawn stores in the U.S., Latin America and the U.K. The company's primary line of business is the operation of retail pawn stores, also known as pawnshops. It also operates a retail POS payment solutions business. Its two business lines are organized into four reportable segments: The U.S. pawn segment consists of pawn operations in some of U.S. states and the District of Columbia; The Latin America pawn segment consists of pawn operations in Mexico, Guatemala, El Salvador and Colombia; The U.K. pawn segment consists of pawn operations in England, Scotland and Wales; and The retail POS payment solutions segment consists of the operations of American First Finance, LLC, which offers products in the U.S.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.